DocDollars

Scilex Pharmaceuticals Inc.

CA · United States · Reporting entity ID 100000221799

Total reported 2019–2025
$4.86M
#718 of 2,960 reporting companies — 0% of all reported industry payments
$2.90M in general payments across 98,247 records, plus $1.97M in research funding across 134 records.

How it breaks down

General payments $2,898,045
Research funding $1,966,297

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Scilex Pharmaceuticals Inc. reported $4.86M to US doctors and teaching hospitals from 2019 to 2025, ranking #718 of 2,960 reporting companies. 40% of that was research funding and 60% general payments such as consulting, speaking, food and travel. 98,247 general payment records and 134 research records were filed.

Common questions about Scilex Pharmaceuticals Inc.

How much has Scilex Pharmaceuticals Inc. paid US doctors?

Scilex Pharmaceuticals Inc. reported $4,864,342 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $2,898,045 in general payments, $1,966,297 in research funding.

How does Scilex Pharmaceuticals Inc. rank among drug and device companies?

It ranks #718 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Scilex Pharmaceuticals Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.